Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Apr;6(3):161-79.
doi: 10.1007/BF02924286.

Experimental study on multidisciplinary treatment of pancreatic cancer

Affiliations

Experimental study on multidisciplinary treatment of pancreatic cancer

T Moriai et al. Int J Pancreatol. 1990 Apr.

Abstract

We investigated the antitumor effects of intratumoral (IT) injection of mitomycin-C (MMC), 5-fluorouracil (5FU), adriamycin (ADR), cisplatin (CDDP), streptozotocin (STZ), and interleukin-2 (IL-2) on well-differentiated pancreatic ductal adenocarcinoma (WD PaCa), a solid tumor model in the Syrian golden hamster. The growth of established palpable WD PaCa was not suppressed by intraperitoneal (IP) injection of these anticancer agents, whereas IT injection of MMC (1.0 mg/kg or more), 5FU (12.5 mg/kg or more), and CDDP (2.5 mg/kg or more) caused significant and marked suppression. The growth of established palpable WD PaCa was transiently suppressed by 50 Gy of local irradiation. The antitumor effect of irradiation was not enhanced by it injection of MMC before irradiation, whereas it was significantly enhanced by it injection after irradiation. Intraperitoneal injection of IL-2 (5 or 10 micrograms/d, 18 d) slightly suppressed the growth of established palpable tumors, but it injection of IL-2 caused significant and marked suppression, eliminating the tumor in 10-20% of the animals. Findings in this animal model of pancreatic cancer suggest that it treatment of anticancer agents or IL-2 might become an effective therapy for advanced pancreatic cancer.

PubMed Disclaimer

Similar articles

References

    1. Cancer. 1983 Nov 1;52(9):1577-82 - PubMed
    1. J Exp Med. 1985 May 1;161(5):1169-88 - PubMed
    1. J Immunol. 1983 Feb;130(2):988-92 - PubMed
    1. Am J Clin Oncol. 1986 Apr;9(2):139-45 - PubMed
    1. Semin Oncol. 1979 Sep;6(3):285-97 - PubMed

Publication types

MeSH terms

LinkOut - more resources